Physician profile
Lloyd Leiva
NPI 1760489983
$1,129.49
in general payments reported to CMS, 2019-2025
25 companies · $79.02 in 2025
The $79.02 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $76.20 · 2021: $27.76 · 2022: $177 · 2023: $284 · 2024: $241 · 2025: $79.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $604.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $138.96 | 2022-2025 | |
| Pfizer INC. | $127.31 | 2019-2025 | |
| Exact Sciences Corporation | $115.84 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $78.76 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $66.74 | 2019-2022 | |
| Amgen INC. | $64.95 | 2019-2025 | Otezla, Repatha, Repatha |
| Abiomed | $58.75 | 2023 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.33 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.00 | 2022-2023 | |
| Avanir Pharmaceuticals, INC. | $43.63 | 2019 | |
| Amarin Pharma, INC. | $39.26 | 2019 | |
| Lilly USA, LLC | $38.12 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $36.31 | 2023-2024 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $27.76 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.94 | 2024 | Eliquis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $24.22 | 2024 | Onpattro |
| Dexcom, INC. | $23.36 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $21.00 | 2019 | |
| Boston Scientific Corporation | $20.98 | 2023 | Watchman Access System |
| Eisai INC. | $17.97 | 2022 | |
| Radius Health, INC. | $16.66 | 2019 | |
| Allergan, INC. | $14.04 | 2020 | |
| Medtronic Minimed, INC. | $11.88 | 2019 | |
| Gilead Sciences, INC. | $11.81 | 2020 | |
| Phathom Pharmaceuticals, INC. | $8.91 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Leiva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.